CIK 0001653087 · Biological Products, (No Diagnostic Substances) (SIC 2836) · Nasdaq · fiscal year ends 12/31
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Revenue (USD) | 21.0 M | 97.1 M | ||
| Net income (USD) | -133.3 M | -36.3 M | -190.2 M | |
| Diluted EPS (USD/shares) | -1.39 | -1.56 |
| Filed | Form | Description | Period |
|---|---|---|---|
| 2026-10-16 | 424B5 | 424B5 | |
| 2026-10-16 | 8-K | 8-K items 1.01,8.01,9.01 | 2026-10-15 |
| 2026-10-16 | FWP | FWP | |
| 2026-10-15 | 4 | 4 | 2026-10-13 |
| 2026-10-15 | 4 | 4 | 2026-10-13 |
| 2026-10-15 | 4 | 4 | 2026-10-14 |
| 2026-10-14 | 8-K | 8-K items 5.02 | 2026-10-13 |
| 2026-10-05 | 8-K | 8-K items 1.01,2.02,7.01,8.01,9.01 | 2026-09-30 |
| 2026-09-18 | SCHEDULE 13G | SCHEDULE 13G | |
| 2026-09-04 | 4 | 4 | 2026-09-02 |
| 2026-09-04 | 4 | 4 | 2026-09-03 |
| 2026-09-04 | 4 | 4 | 2026-09-03 |
| 2026-09-04 | 144 | 144 | |
| 2026-09-02 | 144 | 144 | |
| 2026-09-01 | 144 | 144 | |
| 2026-09-01 | 144 | 144 | |
| 2026-09-01 | 144 | 144 | |
| 2026-08-21 | 4 | 4 | 2026-08-19 |
| 2026-08-06 | 10-Q | 10-Q | 2026-06-30 |
| 2026-08-06 | 8-K | 8-K items 2.02,9.01 | 2026-08-06 |
| 2026-07-09 | 4 | 4 | 2026-07-09 |
| 2026-07-08 | 8-K | 8-K items 1.02 | 2026-07-06 |
| 2026-06-17 | 4 | 4 | 2026-06-17 |
| 2026-06-17 | 4 | 4 | 2026-06-17 |
| 2026-06-17 | 4 | 4 | 2026-06-17 |
Forms on file (last 1,000): 4 274, 8-K 83, 144 71, 3 25, 10-Q 23, SC 13G/A 23, SC 13G 12, SCHEDULE 13G/A 11. Source: SEC EDGAR, as filed; this page is public data and not investment advice.
GET https://store.agentexchange.work/gw/filings/company?ticker=ALEC (0.002 USD), /gw/filings/filings?ticker=ALEC&form=8-K, /gw/filings/facts?ticker=ALEC&concept=Revenues, full-text /gw/filings/search?q=.... Pay per call in USDC (x402) or with a 19 USD card key for 1,000 calls. Catalogue · llms.txtUpdated from EDGAR within 30 minutes of a filing. Agent Exchange